Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 18.88% is 17% below its 5-year average of 22.82%, around the middle of its 5-year range (-11.92%–75.03%).
0.15% above its 12-month average of 18.85%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 28.87%.
NET PROFIT MARGIN
18.88%
NET PROFIT MARGIN AVG TTM
18.85%
NET PROFIT MARGIN AVG 3Y
20.39%
NET PROFIT MARGIN AVG 5Y
22.82%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.15%
CURRENT VS 3Y AVG
-7.43%
CURRENT VS 5Y AVG
-17.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+7361.54%
vs the sector median at left
Harmony Biosciences Holdings, Inc.
Market Cap
$2.28B
Net Profit Margin
18.88%
TTM Avg
18.85%
3Y Avg
20.39%
5Y Avg
22.82%
Market Cap
$2.30B
Net Profit Margin
30.74%
TTM Avg
-487.59%
3Y Avg
-420.36%
5Y Avg
-1671.77%
Market Cap
$2.24B
Net Profit Margin
-40.18%
TTM Avg
-20.09%
3Y Avg
-20.09%
5Y Avg
-20.09%
Market Cap
$2.34B
Net Profit Margin
11.45%
TTM Avg
11.51%
3Y Avg
11.51%
5Y Avg
10.20%
Market Cap
$2.35B
Net Profit Margin
-928.44%
TTM Avg
-334.88%
3Y Avg
-330.91%
5Y Avg
-326.71%
Market Cap
$2.36B
Net Profit Margin
32.98%
TTM Avg
37.58%
3Y Avg
5.36%
5Y Avg
-41.08%
Market Cap
$2.37B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.38B
Net Profit Margin
-0.74%
TTM Avg
-3.79%
3Y Avg
-13.87%
5Y Avg
-19.28%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | $2.28B | 18.88% | 18.85% | 20.39% | 22.82% |
| Liquidia Corporation (LQDA)vs › | $2.30B | 30.74% | -487.59% | -420.36% | -1671.77% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | -40.18% | -20.09% | -20.09% | -20.09% |
| UFP Technologies, Inc. (UFPT)vs › | $2.34B | 11.45% | 11.51% | 11.51% | 10.20% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | -928.44% | -334.88% | -330.91% | -326.71% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 32.98% | 37.58% | 5.36% | -41.08% |
| Disc Medicine, Inc. (IRON)vs › | $2.37B | 0.00% | 0.00% | 0.00% | 0.00% |
| Pharvaris N.V. (PHVS)vs › | $2.17B | 0.00% | 0.00% | 0.00% | 0.00% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | -0.74% | -3.79% | -13.87% | -19.28% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | -37.07% | -63.15% | -35.64% | -15.45% |
Operating Margin
24.0%
Net Profit Margin
18.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 28.87% |
| 2026-03-31 | 15.08% |
| 2025-12-31 | 9.22% |
| 2025-09-30 | 21.24% |
| 2025-06-30 | 19.84% |
| 2025-03-31 | 24.66% |
| 2024-12-31 | 24.58% |
| 2024-09-30 | 24.78% |
| 2024-06-30 | 6.71% |
| 2024-03-31 | 24.79% |
| 2023-12-31 | 15.80% |
| 2023-09-30 | 24.00% |
| 2023-06-30 | 25.56% |
| 2023-03-31 | 24.75% |
| 2022-12-31 | 37.81% |
| 2022-09-30 | 75.03% |
| 2022-06-30 | 21.99% |
| 2022-03-31 | 25.18% |
| 2021-12-31 | 24.90% |
| 2021-09-30 | -11.92% |
| 2021-06-30 | 19.12% |
| 2021-03-31 | 12.38% |
| 2020-12-31 | -0.37% |
| 2020-09-30 | 4.19% |
| 2020-06-30 | -0.07% |
| 2020-03-31 | -194.66% |
| 2019-12-31 | -607.84% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
